31.01.2019
... Impfstoffkandidaten gegen Lyme Borreliose, VLA15. Wolfgang Bender, Chief Medical Officer von Valneva ...
31.01.2019
... Impfstoffkandidaten gegen Lyme Borreliose, VLA15. Wolfgang Bender, Chief Medical Officer von Valneva ...
07.01.2019
... VLA1553’s differentiated target product profile. Wolfgang Bender, Chief Medical Officer of Valneva ...
07.01.2019
... Symptome beobachtet, so das Unternehmen. Wolfgang Bender, Chief Medical Officer von Valneva ...
21.12.2018
... its chikungunya vaccine candidate, VLA1553. Wolfgang Bender, MD, PhD, chief medical officer ...
21.12.2018
... „Fast Track“ Status verliehen hat. Wolfgang Bender, MD, PhD, Chief Medical Officer ...
17.12.2018
... additional, alternative three-dose schedule. Wolfgang Bender, MD, PhD, Chief Medical Officer ...
17.12.2018
... mit 3 Dosen in größeren Abständen. Wolfgang Bender, MD, PhD, Chief Medical Officer ...
20.11.2018
... , alum-adjuvanted whole-virus vaccine. Wolfgang Bender, chief medical officer of Valneva ...
20.11.2018
... gezeigt werden konnte, informiert Valneva. Wolfgang Bender, Chief Medical Officer von Valneva ...